文献速递主动脉疾病

开窗/分支装置用于血管腔内动脉瘤修复术后近端内移植物失败的挽救:文献系统综述与更新Meta分析

Use of Fenestrated/Branched Devices for Rescue of Proximal Endograft Failure After Endovascular Aneurysm Repair: A Systematic Review of the Literature and an Updated Meta-Analysis.
PubMed 文献 · J Endovasc Ther · 2025-03-13

该系统综述与Meta分析纳入截至2024年9月的16项研究共1079例患者,评估开窗/分支血管腔内动脉瘤修复(F/BEVAR)挽救EVAR术后近端内移植物失败的安全性、有效性和耐久性。汇总技术成功率为94.4%,30天/院内死亡率为3.9%,12个月总生存率为88%,36个月免于再干预率为59.3%。作者认为F/BEVAR可行、安全且可靠,中期生存可接受,但再干预不可忽视。

要点

  • F/BEVAR挽救EVAR术后近端内移植物失败的技术成功率为94.4%(95%CI 92.5-95.8)。
  • 30天/院内死亡率为3.9%(95%CI 2.9-5.4),永久性截瘫为1.6%(95%CI 0.8-3.0)。
  • 36个月总生存率为72.2%、免于再干预率为59.3%,作者认为再干预不可忽视。

核心结论

  • F/BEVAR是既往EVAR失败后实现近端内移植物适当密封的可行、安全且可靠的策略。
  • 这些患者的中期生存可接受,而再干预不可忽视。

研究设计与样本

  • 按照PRISMA指南(CRD42024590847)对截至2024年9月的文献进行系统综述。
  • 纳入报告≥10例患者且至少报告一项主要结局的研究,共纳入16项研究、1079例患者。
  • 采用乔安娜布里格斯研究所(JBI)批判性评估工具评估方法学质量和结果稳健性。

主要发现

  • 技术成功率的汇总估计为94.4%(95%CI 92.5-95.8)。
  • 30天/院内死亡率的汇总估计为3.9%(95%CI 2.9-5.4)。
  • 永久性截瘫的汇总率为1.6%(95%CI 0.8-3.0),脑血管事件的汇总率为1.5%(95%CI 0.9-2.8)。
  • 需新开始透析的急性肾功能损害的汇总率为4.4%(95%CI 3.2-6.1),术后呼吸衰竭的汇总估计为7.2%(95%CI 5.5-9.4)。
  • 12个月总生存率的汇总估计为88%(95%CI 83.4-91.4),24个月和36个月生存率分别为79.8%(95%CI 75.6-83.4)和72.2%(95%CI 66.7-77.2);12、24和36个月免于再干预率分别为83.7%(95%CI 79.9-86.9)、75.8%(95%CI 61.0-86.2)和59.3%(95%CI 36.5-78.7)。

临床怎么用

  • 作者认为,F/BEVAR是既往EVAR失败后实现近端内移植物适当密封的可行、安全且可靠的策略。
  • 作者指出,这些患者的中期生存可接受,而再干预不可忽视。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present the current outcomes of fenestrated and branched endovascular aneurysm repair (F/BEVAR) for rescue of proximal endograft failure after endovascular aneurysm repair (EVAR). A systematic review of the currently published literature on F/BEVAR for failed EVAR is undertaken, and the eligible studies are combined into a meta-analysis with the intention of evaluating the safety, efficacy, and the durability of this treatment option. MATERIALS AND METHODS: A systematic review of the literature up to September 2024 was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (CRD42024590847). Studies were included in the meta-analysis if they reported ≥10 patients and at least one of the major outcomes was stated. Primary endpoint was technical success (efficacy). Secondary endpoints included 30-day/in-hospital mortality and morbidity (safety) and survival and reinterventions rate (durability). Methodological quality and robustness of the results of the eligible articles were assessed according to Joanna Briggs Institute (JBI's) critical appraisal tool. RESULTS: A total of 16 studies with overall 1079 patients were included. The pooled estimate for technical success was 94.4% (95% CI 92.5-95.8), whereas for the 30-day/in-hospital mortality 3.9% (95% CI 2.9-5.4). Permanent paraplegia was developed in a pooled rate of 1.6% (95% CI 0.8-3.0), whereas a cerebrovascular event in a pooled rate of 1.5% (95% CI 0.9-2.8). An acute renal function impairment requiring new onset dialysis occurred with a pooled rate of 4.4% (95% CI 3.2-6.1). Postoperative respiratory failure was observed with a pooled estimate of 7.2% (95% CI 5.5-9.4). The pooled estimate for 12-month overall survival was 88% (95% CI 83.4-91.4), and the pooled estimate for 24- and 36-month survival were 79.8% (95% CI 75.6-83.4) and 72.2% (95% CI 66.7-77.2), respectively. Freedom from reintervention was estimated at 83.7% (95% CI 79.9-86.9) for 12 months, 75.8% (95% CI 61.0-86.2) for 24 months and 59.3% (95% CI 36.5-78.7) for 36 months. CONCLUSION: This study showed that F/BEVAR is a feasible, safe, and reliable strategy for achieving proper proximal endograft sealing when previous EVAR has failed. The midterm survival of these patients is acceptable, whereas reinterventions are not negligible.Clinical ImpactThis work summarizes the current experience with fenestrated and branched endovascular aneurysm repair for the rescue of failed endovascular aneurysm repair in the most contemporary meta-analysis including 16 studies with a total of 1079 analyzed patients. Feasibility of the method is proven with a technical success of 94.4%, whereas a 30-day/in-hospital mortality of 3.9% was recorded. The compromised survival and freedom from reinterventions rates (72.2% and 59.3% for 36 months, respectively) pose, however, concerns regarding durability of the method.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Mylonas SN, Papavlasopoulos V, Moulakakis KG, et al. Use of Fenestrated/Branched Devices for Rescue of Proximal Endograft Failure After Endovascular Aneurysm Repair: A Systematic Review of the Literature and an Updated Meta-Analysis. J Endovasc Ther. 2025. PMID: 40079708. doi:10.1177/15266028251325430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。